Universe Pharmaceuticals Inc: stock overview

UPCNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.51

November 13, 2026

DCF calculator

What Ploutos Investor adds for Universe Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from FY2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.
  • A figure that did not match the numbers it is built from has been left out.

In short

Universe Pharmaceuticals had revenue of $17.9B in the fiscal year to September 30, 2025 and a net loss of $3.7B. Revenue grew by 257.2% a year on average over the last 5 years. It holds more cash than debt, by $26.4B. It pays no dividend.

From its SEC filings (latest fiscal year to September 30, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
–
563.3K shares
P/E
–
Revenue, fiscal year
$17.9B
+257.2% a year over 5 years
Net margin
-20.6%
above 33% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

-25.7% a year over 2 years

  • FY2025Sep 30, 202520-F
    Revenue$17.9B
  • FY2024Sep 30, 202420-F
    Revenue$23.0B
  • FY2023Sep 30, 202320-F
    Revenue$32.3B

Fiscal years in figures

UPC's revenue, profit, cash flow and dividend with each year-end price, from FY2019 to FY2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Sorry, we do not have enough data

for the “Valuation” group

Profitability

Gross margin 
35.3%
Operating margin 
-16.3%
Net margin 3-year median: -20.6%
-20.6%
ROIC 
-4.0%
ROIC, 5-year average 
-1.3%
ROE, fiscal year 
-6.5%

Growth

Revenue, yearly change 
-22.4%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+257.2%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$33.6B
Total debt 
$7.1B
Net cash 
$26.4B
Net debt / EBITDA 
–
Interest cover 
-10.1x
Current ratio 
–

Balance sheet of September 30, 2025.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+1,213.8%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

35.3%

Above 43% of the 141 companies in its industry, and 48% of all.

Operating margin

-16.3%

Above 36% of the 285 companies in its industry, and 16% of all.

Net margin

-20.6%

Above 33% of the 302 companies in its industry, and 13% of all.

Revenue growth

-22.4%

Above 8% of the 292 companies in its industry, and 4% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Universe Pharmaceuticals INC
CIK
1809616
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
September 30
Latest annual report
September 30, 2025
Reporting currency
USD
Shares
563.3K

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Universe Pharmaceuticals's filings show?

These are Universe Pharmaceuticals's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about UPC

Didn't find what you were looking for?

Ask us
How much revenue does UPC have?

Universe Pharmaceuticals had revenue of $17.9B in the fiscal year to September 30, 2025. Over the last 5 years it changed by +257.2% a year on average.

Does UPC pay a dividend?

No. Universe Pharmaceuticals paid no regular dividend over the last 12 months.

Where do the figures come from?

From Universe Pharmaceuticals Inc's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.